← Leaderboards
Susan G. Urba
University Of Michigan At Ann Arbor
$225,204
Attributed
$225,204
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $84.4K · FY2005–07$100K$75K$50K$25K$0
'05
'06
'07
Funding mix
By agency
NIH$225,204 · 3
By mechanism
M01$225,204 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- George J Brewer$2,763,501
- Thomas E. Carey$14,226,111
- Steven R Buchman$3,643,078
- Laurence H Baker$13,775,401
- Theodore S Lawrence$30,022,406
Others in their field
Top investigators on “Copper”
- Svetlana Lutsenko · Oregon Health And Science University$18,045,733
- Kenneth D. Karlin · Johns Hopkins University$16,339,237
- Stephen L Buchwald · Massachusetts Institute Of Technology$15,093,202
- Ninian J Blackburn · Oregon Graduate Institute Science &Tech$14,898,278
- Michael J Petris · University Of Missouri-Columbia$14,851,498
- Edward I Solomon · Stanford University$13,845,825
Research focus
CopperAngiogenesis InhibitorsPatient Oriented ResearchHuman Therapy EvaluationHuman SubjectMolybdenumNeoplasm /Cancer ChemotherapyClinical ResearchAngiogenesisChemotherapyEsophagus NeoplasmMetastasisFundingGrantCytokineCaringMalignant Neoplasm Of EsophagusLearningInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseCancer PatientMalignant NeoplasmsHead /Neck NeoplasmGrowth
Grant awards (6)
PRE-OP CHEMORADIATION FOLLOWED BY POST-OP TETRATHIOMOLYBDATE$14,009
M01 · FY2007 · RR · contact PI
PRE-OP CHEMORADIATION FOLLOWED BY POST-OP TETRATHIOMOLYBDATE$43,432
M01 · FY2006 · RR · contact PI
PRE-OP CHEMORADIATION FOLLOWED BY POST-OP TETRATHIOMOLYBDATE$64,845
M01 · FY2005 · RR
TETRATHIOMOLYBDATE IN PATIENTS W/METASTATIC HEAD &NECK CANCER$19,557
M01 · FY2005 · RR
Pre-op Chemoradiation Followed by Post-op Tetrathiomolybdate$56,421
M01 · FY2004 · RR
Tetrathiomolybdate in Patients w/Metastatic Head &Neck Cancer$26,940
M01 · FY2004 · RR